The Lancet Oncology· Jian Zhang, Yehui Shi, Qingyuan Zhang, Yiqun Du, Yanchun Meng, Yongsheng Wang, Qiao Cheng, Xin Chen, Zhihua Li, Yongmei Yin, Jie Dong, Juan Zhang, Feifei Wang, Yankui Ou, Petra Rietschel, Claudia-Nanette Gann, Ilhan Celik, Jiong Wu·· 4 小时前AI 评分34
pumitamig联合白蛋白结合型紫杉醇一线治疗三阴性乳腺癌的活性与安全性：一项单臂I b/II期临床试验
[Articles] Activity and safety of first-line pumitamig plus nab-paclitaxel in triple-negative breast cancer: a single-arm, phase 1b/2 trial
AI 导读
一项单臂I b/II期临床试验显示，pumitamig联合白蛋白结合型紫杉醇（nab-paclitaxel）一线治疗晚期或转移性三阴性乳腺癌具有令人鼓舞的抗肿瘤活性。安全性特征与两种药物的作用机制一致，结果支持在全球II期和III期临床试验中进一步评价。
来源：The Lancet Oncology · thelancet.com